IABCR Journal Header

Article Viewer

Search

Article QR Code

ORIGINAL ARTICLE

10.21276/iabcr.2017.3.4.20
Study of Lipid Profile and High Sensitivity C Reactive Protein in Women with Polycystic Ovary Syndrome
Download PDF     Print

October - December 2017 | Vol 3 | Issue 4 | Page :

Richa Lath 1, Aniruddha Jibhkate 2*, Reshakiran Shendye 3

1 Assistant Professor, Department of Biochemistry; 2Associate Professor, Department of Physiology, Ananta Institute of Medical Sciences & Research Centre, Rajsamand. 3Professor, Department of Biochemistry, Government Medical College, Aurangabad.

How to cite this article: Lath R, Jibhkate A, Shendye R. Study of Lipid Profile and High Sensitivity C Reactive Protein in Women with Polycystic Ovary Syndrome. Int Arch BioMed Clin Res. 2017;3(4):80-83.

ABSTRACT

Background: This study was undertaken to assess the lipid profile parameters and serum levels of high sensitivity C reactive protein (hsCRP) in women with polycystic ovary syndrome. (PCOS). Methods: 80 women diagnosed with PCOS based on Rotterdam ESHRE/ASRM criteria and 40 age matched healthy controls were selected for the study. Anthropometric and biochemical parameters like serum lipid profile and hsCRP were evaluated among these women. Results: Women with PCOS were found to have significantly higher levels of total cholesterol, triglycerides, LDL-C and hsCRP and significantly lower levels of HDL-C as compared to controls. Conclusions: Targeted screening and timely interventions to reduce cardiovascular risk in women with PCOS is necessary to attenuate the complications of the disease.

Keywords: PCOS, Lipid profile, hsCRP.

REFERENCES
  1. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract. 2005;11(2):126-34.
  2. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab. 2010;95(5):2038–2049.
  3. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232-239.
  4. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
  5. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 2009;13(2):90-92.
  6. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
  7. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M et al. Oxidised low-density lipoprotein concentration – early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol. 2006;155(1):131-136.
  8. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048–58.
  9. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89(5):2160–2165.
  10. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61(5):946-951.
  11. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50(12): 2316–2322.
  12. Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet. 2010;281(6):1009–1014.
  13. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C - reactive protein, Interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-334.
  14. Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril. 2009;91(1):213-219.
  15. Al-Youzbaki WB, Abdullah RG. C-reactive protein and lipid profile in patients with polycystic ovary syndrome treated by metformin. Pak J Med Sci 2013;29(2):554-559.
  16. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism. 2003;52(6):713-719.
  17. Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown). 2008;9(10):987-992.

Published by Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.
Publication Manager: Dr. Tayyaba Farhan
Index Copernicus